NPPA demand notice for alleged overcharging on Betaloc-50 pricing

Regulatory & Legal View source PDF Explain this filing

ASTRAZEN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.5%Reaction day

₹8079.50

prior close

₹8079.50

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.5%+1.0% vs market

Pharmaceuticals peers, median of 160sector+0.8%+0.7% vs sector

On the reaction day the stock moved 1.0 pts more than Nifty Microcap 250 and 0.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.7

10m

+1.4

15m

+1.3

30m

+1.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.5+0.5+1.0+0.8+0.7

Next day

+0.4-0.1+0.5-0.0+0.4

+0.3+1.0-0.7+0.1+0.2

+2.7+2.3+0.4+0.6+2.1

+1.6+2.8-1.2+1.0+0.6

+0.4+4.1-3.7+0.6-0.3

+1.5+4.5-3.0+1.6-0.1

15d

-7.2+4.8-12.0+0.5-7.7

-14.0+6.4-20.4+2.1-16.1

-23.0+5.5-28.6+4.2-27.2

-22.1pendingpending-1.9-20.3

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 160Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

AstraZeneca Pharma India received an NPPA demand notice on July 27, 2026 for alleged overcharging on Betaloc-50 tablets under the Drug Prices Control Order 2013. NPPA claims the company sold the tablets above the government ceiling price from June to July 2016. Total demand is Rs 79.97 lakh inclusive of interest, payable in 30 days. The company is reviewing the notice and will take appropriate legal steps.

Likely market impact

Demand of about Rs 80 lakh is small for a large pharma firm, but highlights regulatory risk on drug pricing. Outcome uncertain as the company plans to contest.